Weekender: Sanofi buys an mRNA startup in another bet on 'off-the-shelf' cell therapy

Signup | Forward Weekender April​ 10,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — 81qd 95% Accurate is 100% Wrong in Rare Disease In rare disease patient finding, the focus should be on PRECISION, not ACCURACY. To learn more about our approach please contact us at www.81qd.com.   Sanofi buys an mRNA startup in another bet on 'off-the-shelf' cell therapy Tidal Therapeutics is the second biotech developing more convenient cell therapies that the French pharma has recently acquired, part of a broader expansion in oncology. New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds The influential drug cost watchdog recommended a discount of between 37% and 54% to the $419,500 list price the companies charge for Abecma, a multiple myeloma cell therapy cleared by the FDA in March. Ionis cuts jobs at a former spinout and inks new deal with Sobi Some seven months after acquiring the rest of Akcea Therapeutics, Ionis is laying off most of the subsidiary's staff and turning to Sobi to sell its drugs. Sponsored Content by Thermo Fisher Scientific Your guide to custom mRNA-based therapeutic development Custom products and scalable solutions that take you from early-stage research to commercialization – with continual process optimization. Explore our dedicated mRNA-based therapeutics guide. Acadia, with drug application rejected, calls out FDA for backtracking According to Acadia, the FDA took issue with the main study used in its drug approval submission. That surprised the company, since regulators had never seemed concerned with the study's design. AstraZeneca's coronavirus vaccine possibly linked to rare blood clots, EMA says Europe's drug regulator affirmed the benefits of vaccination outweigh the risks, but recommended the shot's label be updated to warn of the newly established side effect. FibroGen admits misleading safety data for anemia drug, dimming prospects In a surprise announcement, the company said data used to tout the safety of the anemia pill roxadustat included "post hoc changes" that executives only became aware of during regulatory review.  Featured Resources FROM: RxCrossroads by McKesson Adherence can be critical for oncology therapies – what's your strategy? Understanding the Personal Challenges of Adherence Helping Prescribers Provide Adherence Support Investing in Prescriber Engagement and Education From Our Library Trendline Inside the rapidly changing world of gene therapy Trendline What you need to know about oncology's research boom View all resources Best of What We're Reading The New York Times Kati Kariko Helped Shield the World From the Coronavirus The Boston Globe MIT scientists launch Future Founders Initiative to help solve biotech’s ‘missing women’ problem Biocentury CBO report supports biopharma view of value of M&A Barron's How a Simple Blood Test Could Reduce Cancer Deaths POLITICO Senior Trump and Biden officials knew for months about problems at vaccine plant Chemical & Engineering News Pfizer unveils its oral SARS-CoV-2 inhibitor Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip